Sohanya Roshan Cheng - 28 Feb 2023 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Commercial Officer
Signature
/s/Nancy Smith as Attorney-in-Fact for Sohanya Cheng
Issuer symbol
KPTI
Transactions as of
28 Feb 2023
Net transactions value
-$34,045
Form type
4
Filing time
02 Mar 2023, 16:33:39 UTC
Previous filing
01 Sep 2022
Next filing
12 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +100,000 +82% $0.000000 221,926 28 Feb 2023 Direct F1, F2
transaction KPTI Common Stock Sale $34,045 -11,239 -5.1% $3.03 210,687 01 Mar 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
F2 Includes 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2022.
F3 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.